From Schedule I to III: What the DOJ’s Medical Marijuana Reclassification Means for Alabama and Multistate Employers

The U.S. Department of Justice’s April 2026 order reclassifying certain marijuana products from Schedule I to Schedule III under the Controlled Substances Act marks a seismic shift in federal drug policy—and raises urgent questions for employers navigating workplace drug policies, disability accommodation requests under the ADA, and drug testing programs. The speaker will discuss the order’s key distinctions, including the divide between medical and non-medical use, the unsettled implications for DOT-regulated workforces, and the continued relevance of existing state law obligations. The speaker will also discuss the potential ADA-related claims and risks facing Alabama employers, particularly now that Alabama’s medical marijuana program is operational after years of delays following the law’s 2021 passage. Attendees will receive practical, business-focused guidance on how to audit their current drug policies and effectively position their organizations for this new landscape.